Literature DB >> 7849170

Activity and activation of the complement system in patients being operated on for cancer of the colon.

G Baatrup1, N Qvist, A Junker, K E Larsen, C Zimmermann-Nielsen.   

Abstract

OBJECTIVE: To find out if there was any local activation of complement in the vicinity of a colonic cancer, and any fluctuation in the function of the complement system during operation.
DESIGN: Prospective study.
SETTING: One university and two district hospitals in Denmark.
SUBJECTS: 29 selected patients undergoing emergency and elective operations for colonic cancer.
INTERVENTIONS: Measurements of systemic and local complement fixation capacity and complement activation in samples of serum or plasma taken before, during, and after operation. MAIN OUTCOME MEASURES: Changes in complement fixation capacity and complement activation during operation.
RESULTS: Haemodilution during operation caused a significant reduction in the complement fixation capacity of serum and in the activation of the complement system as measured by generation of C3c. We were unable to confirm the presence of complement inhibitors during operation. Haemodilution caused a 30% reduction in fixation capacity of C3b (12/29 samples of serum had values more than 2SD below the mean of the reference range compared with 4/29 before operation). The activity of C4 was reduced by 25% during operation and the capacity of the complement system to fix C3b and C4b was restored to baseline nine days postoperatively. Concentration of C3d was significantly higher in serum from tumour venous blood compared with that from peripheral blood during operation.
CONCLUSION: The presence of complement activation products in the general circulation reflects local activation of the complement system in the vicinity of the tumour, but this may have been influenced by tissue necrosis or subclinical infection. Haemodilution causes a significant reduction in the capacity of the complement system during operation, whereas inhibitory factors associated with the cancer or operation and anaesthesia could not be demonstrated. We found no correlation between complement activity and clinical data.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7849170

Source DB:  PubMed          Journal:  Eur J Surg        ISSN: 1102-4151


  8 in total

Review 1.  Is complement good or bad for cancer patients? A new perspective on an old dilemma.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Trends Immunol       Date:  2009-05-08       Impact factor: 16.687

Review 2.  The role of the complement system in cancer.

Authors:  Vahid Afshar-Kharghan
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

Review 3.  Unwelcome complement.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

Review 4.  Targeting complement-mediated immunoregulation for cancer immunotherapy.

Authors:  Martin Kolev; Maciej M Markiewski
Journal:  Semin Immunol       Date:  2018-02-15       Impact factor: 11.130

Review 5.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

6.  Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells.

Authors:  Angeliki Korpetinou; Spyros S Skandalis; Aristidis Moustakas; Kaisa E Happonen; Heidi Tveit; Kristian Prydz; Vassiliki T Labropoulou; Efstathia Giannopoulou; Haralambos P Kalofonos; Anna M Blom; Nikos K Karamanos; Achilleas D Theocharis
Journal:  PLoS One       Date:  2013-10-31       Impact factor: 3.240

7.  C5b-9 Staining Correlates With Clinical and Tumor Stage in Gastric Adenocarcinoma.

Authors:  Jian Chen; Wei-Jun Yang; Hai-Jian Sun; Xia Yang; Yu-Zhang Wu
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-08

Review 8.  Complementing Cancer Metastasis.

Authors:  Dawn M Kochanek; Shanawaz M Ghouse; Magdalena M Karbowniczek; Maciej M Markiewski
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.